20/20 Gene Systems

20/20 GeneSystems is a digital diagnostics company focused on reducing cancer mortality through early detection. The company operates in the healthcare sector, providing AI-driven cancer screening tests that utilize a broad panel of tumor markers and personal clinical factors. Their flagship product, OneTest, is designed for high-risk lung cancer patients and is available both in the U.S. through their CLIA lab and internationally as a SaaS solution for health screening clinics. Additionally, they offer a Suspicious Powder Screening Kit to identify biological materials in unknown powders and COVID-19 antibody testing products. The company serves healthcare providers, clinics, and high-risk individuals. Their business model includes direct sales of diagnostic tests, SaaS subscriptions, and equity crowdfunding. Revenue is generated through the sale of diagnostic tests and subscription fees for their SaaS platform. Keywords: AI-driven diagnostics, cancer screening, early detection, lung cancer, tumor markers, SaaS, health screening, COVID-19 testing, equity crowdfunding, digital diagnostics.